It could be something as simple as an abnormally high number of CCR5 delta 32 single allele or even a few CCR5 delta 32 double allele deletion patients. Although double allele patients should be excluded in all our trials. It would even be beneficial to results to exclude single allele. With such a small trial only a few could skew results.

They say the statistically significant results in 700mg is from a group with a haplotype that expresses a higher CCR5 amount than placebo. There are other CCR5 types outside of allele number that do lower CCR5 but they don't lower it even as much as single allele. There are also some CCR5 haplotypes that have a greater expression than normal.

Quote:

---

and in the 700 mg group with genetic haplotypes known to over produce CCR5 compared to placebo (-27.9% vs +9.85%, p = 0.006 and - 45.4 ms vs +27.64 ms, p = 0.013)

---